Back to search
FDAFDA · Food and drugs·Recall number Z-2413-2024

Orthopantomograph OP300 dental computed tomography x-ray system. The X-ray device produces conventional 2D X-ray images and Xray projection images for the reconstruction of a 3D view. The device is operated and used by qualified healthcare professionals.

Published August 21, 2024 · Recall initiated: October 28, 2021

Summary

FDA records medical device Class II recall Z-2413-2024, published August 21, 2024 and initiated October 28, 2021. Recalling firm: Palodex Group Oy; Status: Ongoing; Reported quantity: 103; Lot: DI: 06430035872725, 06430035872732, 06430035872749, 06430035872756, 06430035872763, 06430035872770. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

It was noticed in production on 28.10.2021, that the final testing database gives a pass result for Pan ADC repeatability test even when the test result is not within the set acceptance criteria (repeatability within 4%).

What to do

FDA Mandated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Palodex Group Oy
Distributor
US Nationwide-Worldwide
Lot
DI: 06430035872725, 06430035872732, 06430035872749, 06430035872756, 06430035872763, 06430035872770
Risk classification
Class II
Area (FDA)
device
Country
Finland

Related recalls

Questions about this recall

Was Orthopantomograph OP300 dental computed tomography x-ray system. The X-ray device produces conventional 2D X-ray images and Xray projection images for the reconstruction of a 3D view. The device is operated and used by qualified healthcare professionals. recalled?

Yes. FDA published recall Z-2413-2024 on August 21, 2024. Reported hazard: It was noticed in production on 28.10.2021, that the final testing database gives a pass result for Pan ADC repeatability test even when the test result is not within the set acceptance criteria (repeatability within 4%).

What should I do if I have this product?

FDA Mandated · Letter